Select Scientific POSTERS

RevIEW POSTERS BY YEAR

2017

Quantification of Rare PD-L1 and Other Immunology Biomarker Expressing Leukocytes and CTCs in Peripheral Blood of Cancer Patients. EORTC

Comprehensive Single Cell Analysis of Tumor Mutation Burden (TMB), Chromosomal Instability (CIN), and Microsatellite Instability (MSI) on Circulating Tumor Cells (CTCs). EORTC

Phenotypic Circulating Tumor Cell (CTC) Classifier of Genomic Instability (GI) Associates with Improved Overall Survival (OS) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Receiving Platinum Agents in Addition to Taxanes. ESMO

Integrated Single Cell Phenogenomic Subtyping of CTCs Identify Inter-Cellular Tumor Heterogeneity (het) and Multiple Resistance Mechanisms in mCRPC Patients (pts). ASCO GU

Quantification of Rare PD-L1 and Other Immunology Biomarker Expressing Leukocytes and CTCs in Peripheral Blood of Cancer Patients. AACR

Phenotypic, Genomic, and Clinical Associations of Circulating Tumor Cells (CTCs) Lacking Epithelial Biomarkers in Metastatic Castration Resistant Prostate Cancer (mCRPC). AACR

Changes in CTC burden and phenotypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapeutics (Tx)

Baseline Circulating Tumor Cell (CTC) Subtype Predicts Responses to Enzalutamide but Not Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) prognosticates poor overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi)

2016

Single CTC Characterization Identifies Phenotypic and Genomic Heterogeneity as a Mechanism of Resistance to AR Signaling Directed Therapies (AR Tx) in mCRPC Patients. ASCO GU 2016.

Clinical Validation of CTC Subtype Frequency to Prognosis Overall Survival (OS) in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Patients. ASCO GU 2016

Validation of AR-V7 as a Treatment-Specific Biomarker at Decision Points in Management of Castration-Resistant Prostate Cancer. AACR 2016

Androgen receptor expression on circulating tumor cells (CTCs) in metastatic breast cancer. AACR 2016

Programmed Death-1 Ligand (PD-L1) Expression on Circulating CD45(-) Cells is an Independent Prognostic Factor for Overall Survival in Patients with Lung Cancer. ASCO 2016

AR-V7 Status and CTC Heterogeneity Improve the Prediction of Drug Sensitivity and Patient Outcomes for Taxanes and Approved AR Targeted Therapies ASCO 2016

CTC phenotype classifier identifies mCRPC patients with high genomic instability CTCs and predicts failure of Androgen Receptor signaling (AR Tx) and taxane systemic therapies ASCO 2016

Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients with castration-resistant prostate cancer (CRPC). ASCO 2016

Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifier in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial

2015

Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC). ASCO 2015

Programmed death-ligand 1 (PD-L1) Characterization of Circulating Tumor Cells (CTCs) and White Blood Cells (WBCs) in Muscle Invasive and Metastatic Bladder Cancer Patients. ASCO GU 2015

Review posters by Indication

Breast cancer studies Prostate cancer studies

Lung cancer studies Bladder cancer studies

Our mission is to improve patient lives by enabling precision medicine with non-invasive tests that profile rare cells in cancer.

NAVIGATION

UP to date with Epic Sciences

JUST RELEASED: AR-V7 as an indication for treatment selection

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: June 4, 2016. DOI:10.1001/jamaoncol.2016.1828